CHÉOS has a long history of implementing and supporting clinical trials across a range of disciplines.
Clinical trials are the most rigorous method for addressing clinical research questions; however, they are resource-intensive and require high-level expertise to design and conduct. Our scientists are active in the areas of study methodology and health outcomes measurement.
Program Head: Dr. Joel Singer
At CHÉOS, our staff have over 30 years of experience in all aspects of clinical trials, from design of data capture instruments to database issues, conduct, analysis, and oversight of trials.
CHÉOS has an in-house team of clinical trial experts, who are available to facilitate and assist external investigators with the development and conduct of their clinical trials. View our Clinical Research Support page for more information.
Program Head Dr. Joel Singer’s primary area of expertise is on methodological and analytical issues in clinical trials, and he has considerable experience with methodological issues in observational trials.
Here is a sampling of current and past clinical trials and observational studies:
NaMaSTe is a randomized controlled trial to assess the impact of a novel culturally-tailored lifestyle and medication adherence intervention in South Asian patients with poorly controlled diabetes in Canada. Under the direction of CHÉOS Scientist Dr. Nadia Khan, the study aims to recruit 600 participants from British Columbia with type 2 diabetes.
South Asians living in Canada and globally have high rates of type 2 diabetes. Despite the burden of diabetes in this population, diabetes management remains poor. South Asian patients are less likely to exercise, follow a healthy diet, participate in exercise programs, and achieve glucose, blood pressure, and lipid targets for diabetes than the general population. Although there is some preliminary evidence that culturally-tailored chronic disease models may improve outcomes, the current evidence base is insufficient to justify the system modifications required to provide this type of care across primary care settings in Canada. The NaMaSTe trial, therefore, endeavours to increase the body of evidence to assist in improving the health of South Asian patients in Canada.
The NAOMI trial began enrolment in Vancouver and Montreal in 2005, with the study completing in 2008. Dr. Martin Schechter was the study’s principal investigator, and CHÉOS Scientists Drs. Aslam Anis, Eugenia Oviedo-Joekes and Joel Singer were among the co-investigators. NAOMI was a randomized trial of patients who were not currently benefiting from conventional treatment. Results from NAOMI showed that participants with a chronic opioid addiction who were treated with diacetylmorphine were more likely to stay in treatment or quit heroin altogether, and more likely to reduce their use of illegal drugs and other illicit activities than patients who used methadone maintenance treatment.
- Tissue plasminogen activator in cardiac arrest with pulseless electrical activity: a randomized placebo-controlled trial (Publication Link)
- Randomized trial of a ‘virtual’ cardiac rehabilitation program delivered at a distance via the internet (ClinicalTrials.gov)
- Evolution and impact of the Vancouver Coastal Health Authority regional reperfusion system for ST-elevation myocardial infarction (Publication Link)
- Prospective randomized clinical trial of early amniocentesis and midtrimester amniocentesis: Primary evaluation comparing procedure safety and fetal outcome (The Canadian Early and Midtrimester Amniocentesis (CEMAT) Group) (Publication Link)
- Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure (Publication Link)
- Control of Hypertension in Pregnancy Study (CHIPS): Less-tight versus tight control of hypertension in pregnancy (Publication Link)
- A Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates
- Kidney transplant candidates are at high risk for coronary artery disease and currently undergo annual testing to determine if they have developed the disease. As the optimal strategy to monitor and maintain the cardiac fitness of kidney transplant candidates is unknown, this study will determine whether annual testing is in fact necessary. The study is expected to influence transplant practice worldwide, as the results will either a) make better use of scarce deceased-donor kidneys by permitting better wait list management, or b) save valuable resources due to averting needless and potentially detrimental tests in asymptomatic patients. CHÉOS Scientist Dr. John Gill is a principal investigator on the trial. More information at ClinicalTrials.gov.
- A nurse-coordinated based model of care versus usual care for Stage 3/4 chronic kidney disease in the community: A randomized controlled trial (Publication Link)